OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
TCRT
Alaunos Therapeutics, Inc.
There isn't enough reported data to score TCRT yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
TCRT Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
TCRT's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
TCRT PE Valuation
TCRT has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
TCRT Forward outlook
There aren't enough analyst estimates for TCRT to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over TCRT on earnings quality, reporting a profit while its opponent remains loss making.
TCRT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.90 | +$0.51 |
| Q1 2026 | -$2.12 | +$0.37 |
| Q4 2025 | -$2.20 | +$0.72 |
| Q3 2025 | -$2.26 | +$4.25 |
| Q2 2025 | -$2.41 | +$9.40 |
| Q1 2025 | -$2.49 | +$14.61 |
| Q4 2024 | -$2.92 | +$19.08 |
| Q3 2024 | -$6.51 | +$15.99 |
TCRT is still losing money, but far less than before: $1.90 per share over the past year, against $105.00 at its worst in early 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over TCRT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
TCRT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $3K | -25% |
| Q1 2025 | $2K | +100% |
| Q4 2024 | $4K | +300% |
| Q2 2024 | $4K | 0% |
| Q4 2023 | $1K | -91% |
| Q3 2022 | $2.9M | +631% |
TCRT's revenue has slid since its 2022 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -30233% | -11358 points |
| Q1 2025 | -54600% | +119600 points |
| Q4 2024 | -18875% | +776025 points |
| Q2 2024 | -29150% | +170400 points |
| Q1 2024 | -174200% | N/A |
| Q4 2023 | -794900% | -717436 points |
| Q2 2023 | -199550% | N/A |
| Q4 2022 | -77464% | N/A |
TCRT's operating margin was −30233% last quarter, up 143967 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with TCRT at up 93%.
TCRT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$300K | +$401K |
| Q1 2026 | -$1M | -$259K |
| Q4 2025 | -$553K | +$39K |
| Q2 2025 | -$701K | +$980K |
| Q1 2025 | -$772K | +$1.1M |
| Q4 2024 | -$592K | +$6.8M |
| Q3 2024 | -$781K | +$5.6M |
| Q2 2024 | -$1.7M | +$5.5M |
TCRT has burned cash in almost every quarter: −$3M over the past year, against −$4M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over TCRT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
TCRT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +25% | +483K shares |
| 1 year | +45% | +755K shares |
| 3 years | +52% | +833K shares |
| 5 years | +70% | +1M shares |
| Available history | +114% | +1.3M shares |
TCRT has 2M diluted shares, up 45% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q4 2022 | — |
| Q4 2019 | $283,000 |
| Q3 2019 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
TCRT Net Leverage
TCRT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
TCRT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.5 | Neutral |
| Stochastic | 28.6 | Neutral |
TCRT's weekly RSI is 45 (neutral) and its Stochastic is 29 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
TCRT PE vs Healthcare Sector
| Metric | TCRT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TCRT has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over TCRT on trend strength, trading above more of its moving averages.
TCRT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.61 | 0.6% above |
| 20 week MA | $1.73 | 6.4% below |
| 50 week MA | $2.43 | 33% below |
| 100 week MA | $2.50 | 35% below |
| 200 week MA | $17.4 | 91% below |
TCRT has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 91% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over TCRT on returns for 2026, with the stronger performance.
TCRT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $772.5 | $432.0 | -44% |
| 2021 | $432.0 | $189.0 | -56% |
| 2022 | $189.0 | $88.2 | -53% |
| 2023 | $88.2 | $10.6 | -88% |
| 2024 | $10.6 | $1.84 | -83% |
| 2025 | $1.84 | $3.23 | +76% |
| 2026 YTD | $3.23 | $1.62 | -50% |
TCRT has finished lower in five of the last six years. It's down 50% so far in 2026.